Posted by Michael Wonder on 10 Nov 2020
Bausch Health Canada receives a positive recommendation from the CADTH Canadian Drug Expert Committee for Duobrii - a novel topical anti-psoriatic prescription drug
10 November 2020 - Positive CADTH recommendation moves Duobrii closer to federal, provincial and territorial drug plan reimbursement.
Bausch Health, Canada today announced that the CADTH Canadian Drug Expert Committee issued a positive recommendation for Duobrii (0.01% w/w halobetasol propionate and 0.045% w/w tazarotene), a combination product composed of a corticosteroid and a retinoid pro-drug.
